Elevated parathyroid hormone levels in older women treated for osteoporosis using denosumab

[1] Lewiecki EM(2019)Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States JBMR Plus 3 92-104

[2] Ortendahl JD(2018)Osteoporosis: a review of treatment options P t 43 444-449

[3] Vanderpuye-Orgle J(2017)Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women J Musculoskelet Neuronal Interact 17 47-51

[4] Grauer A(2013)The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies Clin Cases Miner Bone Metab 10 1353-1363

[5] Arellano J(2016)Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study J Clin Endocrinol Metab 101 499-503

[6] Lemay J(2013)Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis Clin Endocrinol (Oxf) 79 214-216

[7] Harmon AL(2018)Denosumab-induced normocalcemic hyperparathyroidism in a woman with postmenopausal osteoporosis and normal renal function Curr Drug Saf 13 122-53

[8] Broder MS(2013)Dramatic increase in parathyroid hormone and hypocalcaemia after denosumab in a kidney transplanted patient Clin Kidney J 6 48-336

[9] Singer AJ(2006)Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature Endocr Pract 12 335-623

[10] Tu KN(2004)Severe hypocalcaemia after being given intravenous bisphosphonate BMJ 328 608-368

[1] Lewiecki EM(2019)Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States JBMR Plus 3 92-104

[2] Ortendahl JD(2018)Osteoporosis: a review of treatment options P t 43 444-449

[3] Vanderpuye-Orgle J(2017)Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women J Musculoskelet Neuronal Interact 17 47-51

[4] Grauer A(2013)The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies Clin Cases Miner Bone Metab 10 1353-1363

[5] Arellano J(2016)Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study J Clin Endocrinol Metab 101 499-503

[6] Lemay J(2013)Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis Clin Endocrinol (Oxf) 79 214-216

[7] Harmon AL(2018)Denosumab-induced normocalcemic hyperparathyroidism in a woman with postmenopausal osteoporosis and normal renal function Curr Drug Saf 13 122-53

[8] Broder MS(2013)Dramatic increase in parathyroid hormone and hypocalcaemia after denosumab in a kidney transplanted patient Clin Kidney J 6 48-336

[9] Singer AJ(2006)Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature Endocr Pract 12 335-623

[10] Tu KN(2004)Severe hypocalcaemia after being given intravenous bisphosphonate BMJ 328 608-368